Therapeutics Company Announces Major Clinical Collaboration With Merck
Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
Disclaimer: The following article provides an in-depth look at the clinical collaboration between Prelude Therapeutics and Merck. This content is for informational purposes only and does not constitute medical advice or commercial promotion of the companies or products mentioned.
Real-time information is available daily at https:/…